Does 'andropause' in men actually compare to menopause in women?

What's this video probably claiming?

Based on the caption and hashtag pairing of #Wechseljahre (German for menopause) with #Andropause, this creator is likely arguing that men experience a hormonal transition analogous to female menopause, that it gets overlooked or dismissed, and that it deserves the same clinical attention. The framing "Wechseljahre = Frauensache? Nein" (menopause is a women's issue? No) suggests the video positions andropause as an underdiagnosed condition affecting men equally. Given the TRT category tag and the platform's audience, it's a fair assumption the creator is also gesturing toward testosterone replacement therapy as a logical response to these changes. That part deserves scrutiny, because the science on how closely male hormonal aging mirrors menopause is more complicated than a short-form video can responsibly handle.

What does the science actually show?

Men do experience age-related testosterone decline. The Massachusetts Male Aging Study documented a cross-sectional decline of roughly 1.6% per year in total testosterone after age 40, and longitudinal data puts free testosterone decline closer to 2-3% annually (Harman et al., 2001, Journal of Clinical Endocrinology and Metabolism). But here's where the menopause comparison gets shaky: female menopause involves a rapid, near-complete cessation of ovarian estrogen production within a few years. Male testosterone decline is gradual and partial. By age 70, average testosterone levels are roughly 35% lower than at age 25, but the majority of men remain within what labs classify as the normal range. A 2010 study in the New England Journal of Medicine (Bhasin et al.) estimated that symptomatic late-onset hypogonadism, meaning low testosterone plus specific clinical symptoms, affects somewhere between 2% and 6% of men aged 40-70. That is not a universal male biological event in the way menopause is.

Where does the social media noise diverge from clinical reality?

The term "andropause" itself is contested. The Endocrine Society and most major clinical bodies do not formally recognize andropause as a diagnosis. Their preferred term is late-onset hypogonadism or age-related hypogonadism, which requires both biochemical confirmation (typically two fasting morning testosterone readings below 300 ng/dL) and specific symptoms. Social media content in this space tends to conflate normal aging symptoms such as fatigue, reduced libido, and mood changes with a diagnosable hormonal disorder requiring treatment. That conflation matters because TRT is not a benign intervention. A 2023 New England Journal of Medicine trial (Lincoff et al., TRAVERSE study) found that TRT in middle-aged men with hypogonadism was non-inferior to placebo for major cardiovascular events, which addressed some safety concerns, but also noted elevated rates of atrial fibrillation, pulmonary embolism, and acute kidney injury in the testosterone group. Treating normal hormonal aging as a pathology requiring medication is not a risk-free call.

What should you actually know?

If you're a man over 40 experiencing fatigue, low libido, depression, or reduced muscle mass, those symptoms are worth discussing with a physician. But they have a long list of potential causes beyond testosterone levels, including sleep apnea, hypothyroidism, depression, and metabolic syndrome. Diagnosis requires actual lab work, not a TikTok checklist. The real value in content like this is reducing stigma around men seeking hormonal evaluations. The risk is that it creates demand for TRT in men who don't meet clinical criteria. A 2020 JAMA Internal Medicine analysis found that nearly one in four men prescribed TRT between 2009 and 2016 had no documented testosterone measurement beforehand. Better awareness should translate into better clinical evaluation, not direct-to-consumer hormone optimization framing.